ArticleChinese medicine2025
Decoding the anti-thrombotic effects of leonurine: a multimodal approach combining TCM repositioning and mTOR signaling.
Article in Chinese medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundAs a natural small molecule compound, Leonurine have great potential for application in the treatment of cardiovascular diseases. However, there is still a gap in the treatment of thrombosis with Leonurine.
methodsA multimodal heterogeneous network is constructed using ETCM and STRING databases, integrating herbs, ingredients, targets and diseases. A reposition model constructed by random walk and random forests is used to predict the relationship between Leonurine and diseases. In addition, network pharmacology, molecular docking and molecular dynamics are used as computer-aided methods to confirm the target of Leonurine. Finally, CCK-8 assay, Flow cytometry, Western Blotting, and mouse experiments are used to validate the therapeutic potential of Leonurine from the perspective of biological wet experiments.
resultsFirstly, based on the accurate prediction results evaluated by indicators, Leonurine is evaluated to have potential therapeutic effects on thrombotic diseases. Through computer-aided methods, mTOR is identified as a potential regulatory factor and may have a similar regulatory mechanism to the marketed drug Everolimus. Experimental results demonstrate that Leonurine reduces thrombotic cell apoptosis and promotes endothelial cell proliferation by inhibiting mTOR signaling. Additionally, in vivo studies show decrease mTOR expression in thrombotic tissues following Leonurine treatment.
conclusionsThese findings underscore mTOR's critical role in mediating Leonurine's anti-thrombotic effects, supported by both computational and experimental evidence. The study provides a foundation for the application of TCM-derived compounds in modern medicine, particularly in thrombosis treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.